Granted Patent
B2
US 9,216,189 · App. 13/575,220 · Granted Dec 22, 2015
Antibodies which bind type I cannabinoid receptor/angiotensis II receptor heteromers
Assignee:
Icahn School of Medicine at Mount Sinai
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Compounds and compositions useful for the treatment of liver diseases and methods of treating liver diseases are disclosed. The compounds of the invention specifically interact with heteromers of cannabinoid receptors as compared to monomers or homodimers. The invention also relates to methods of screening for compounds useful for the treatment of liver diseases and to methods of screening for diacylglycerol lipase inhibitors.
Claims (2)
1. An isolated monoclonal antibody which specifically binds to a type I cannabinoid receptor (CB 1 R)/angiotensin II receptor (AT1R) heteromer.
2. A pharmaceutical composition comprising the monoclonal antibody of claim 1 and a pharmaceutically acceptable carrier or diluent.
Assignments (2)
CONFIRMATORY LICENSE
Recorded Sep 5, 2014
From: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 033692/0658 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 13, 2013
From: DEVI, LAKSHMI; ROZENFELD, RAPHAEL
To: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Reel/Frame 029985/0331 →
Continuity (2)
Provisional Application
61297895
· Jan 25, 2010